PharmaSUG 2025 - Paper LS-285

Programming Challenges in Master Protocols

Vijaya.L.Jonnalagadda, Revolution Medicines

ABSTRACT

Master protocols are becoming increasingly vital in clinical trials, as they facilitate the simultaneous evaluation of multiple treatments or hypotheses within a single, unified trial framework. However, the adoption of master protocols presents unique programming challenges that must be carefully considered by management teams.

In clinical trials, master protocols allow for the concurrent testing of several treatments or strategies, optimizing resource use and enabling real-time adjustments based on interim analyses. This paper explores the statistical programming challenges that arise during the design, execution, and analysis phases of such trials, including the development of dynamic programming and the integration of adaptive designs. The paper also highlights the role of statistical programmers in addressing issues such as data consistency, the complexity of managing data from single or separate databases, flexibility in programming, and compliance with regulatory guidelines—issues that are magnified in master protocol designs.

The paper concludes by offering recommendations for statistical programming best practices, emphasizing the importance of automation, robust validation, thorough documentation, and discusses how current and future leaders can effectively navigate these complexities for mitigating risks and improving efficiency to ensure the successful implementation and scalability of master protocol trials. Furthermore, the paper highlights how adopting these best practices can significantly improve professional development by providing current/future programming leaders with the knowledge to enhance their expertise and stay abreast of industry advancements.

INTRODUCTION

Traditional clinical trials typically follow a prespecified design, with a fixed number of participants, predetermined treatment arms, and a set duration to test a specific hypothesis. In contrast, newer trial designs, such as master protocols, introduce flexibility. These designs can accommodate multiple treatment arms for either a single or a range of treatments, and the duration of the study can vary. In other words, master protocols provide a highly adaptable framework, enabling trials to be more responsive to emerging data.

Given the flexibility inherent in these designs, they present unique challenges. However, this flexibility allows for the testing of multiple treatments for a single disease or multiple diseases with a single treatment, all within one trial. This approach significantly reduces the time and cost typically associated with conducting separate, traditional trials for each hypothesis, making the process more efficient.

Ultimately, understanding the objectives of master protocols and having clear expectations will help programmers navigate the inherent complexities of these adaptive trial designs. By maintaining a flexible yet structured approach, master protocols can efficiently lead to meaningful insights, even when the path forward isn't always straightforward.

MASTER PROTOCOLS OVERVIEW

A master protocol is defined as a protocol designed with multiple substudies, which may have different objectives and involve coordinated efforts to evaluate one or more investigational drugs in one or more

disease subtypes within the overall trial structure. The sponsor can design the master protocol with a fixed or an adaptive design with the intent to modify the protocol to incorporate or terminate individual substudies within the master protocol.

There are three types of master protocols. A **basket trial** tests a single investigational drug or combination across different populations, defined by cancer type, disease stage, histology, prior therapies, biomarkers, or demographics. An **umbrella trial** evaluates multiple investigational drugs, alone or in combination, within a single disease population. **Platform trials** combine features of both, allowing the evaluation of multiple drugs and regimens across various tumor types. The design among these types are not rigid and might overlap with each other as shown in Figure 1 which adds to the complexity.

Master protocols have gained significant traction because they offer an opportunity to conduct studies in a faster, more cost-effective manner while still addressing important clinical questions. That said, the design's flexibility also means that there are many unknowns. These uncertainties can make it more challenging to predict outcomes and complexities to programming. A structured approach to understanding and addressing these challenges is essential for successful implementation.



Figure 1. Types of Master Protocols

STATISTICAL PROGRAMMER ROLE AND CHALLENGES

A statistical programmer in a clinical trial typically handles several key responsibilities, including retrieving raw data, cleaning it, and performing analyses by creating analysis datasets, such as SDTM (Study Data Tabulation Model) and ADaM (Analysis Data Model) using tools like the protocol and statistical analysis plan (SAP). Once these datasets are prepared, the programmer generates analysis findings in the form of tables, listings, and figures, often guided by mock shells. Finally, the programmer assembles various data packages for submission to regulatory authorities.

Given the numerous unknowns at each of these stages in a master protocol, statistical programmers often face various challenges in fulfilling the above roles which are quite straightforward in a traditional

trial. While individual contributors are deeply involved in hands-on programming and execution of these tasks, those in leadership positions focus more on the overall success of the project, process improvements, and foster cross-functional collaboration.

Let's explore the specific challenges encountered at each stage of this process.



Figure 2. Programming Challenges and Best practices in a master protocol

CHALLENGES WITH RETREIVING DATA

To begin the analysis, a statistical programmer must first gain a clear understanding of how the data is collected and the variables within the datasets. In the case of master protocols, the database could either be combined across all separate protocols or maintained separately for each. In some instances, a hybrid approach may be used, where a few subprotocols share a combined database while others remain separate.

Given the flexible nature of master protocols, it's common to see multiple Case Report Form (CRF) migrations, especially to accommodate amendments. With the ongoing changes to the source data, the statistical programmer must continuously adapt to modifications, such as additions, deletions, and changes to variables.

When dealing with a combined database, a key challenge is deciding whether to keep the analysis datasets combined or separate. Keeping datasets combined can offer time and resource efficiencies, but this approach can become complex as the trial progresses. On the other hand, separating the datasets has its own set of advantages and challenges. While maintaining separate datasets may reduce complexity, it requires additional effort to ensure code consistency.

CHALLENGES WITH ANALYZING DATA

In a traditional set up, we have a clear idea on many aspects of the trial, at least the number of treatment arms will be a known thing. In master protocols, as there is a flexibility to add or remove therapies at any stage of the trial, it becomes very tricky to derive the treatment related variables, particularly so when the database is combined.

During the journey of these trials, present treatments are reviewed intermittently to decide what treatments are working and what are not. Typically, the results may be that some of the treatment(s) might be showing very good results, while some might result in adverse events and while some others may not be very efficient but are still promising. Based on these, decisions will be made whether to continue or stop or add new treatment or add more combinations of treatments. Sometimes the analysis itself might be changes with new endpoints. Adding to the complexity, treatments can be switched; subjects can be switched.

All these decisions mean that, with new treatments added, new variables will have to be added in multiple domains like trial design datasets, drugs related adverse events, action taken on the different study treatments, treatment start dates, termination reasons etc. to mention a few. ADaM data sets are never final and constantly need to be updated.

CHALLENGES WITH CREATING REPORTS

The evolving nature of master protocols necessitates continuous updates to reporting templates, particularly when new treatments are introduced, requiring additional columns and subgroup analyses. As the trial progresses, the focus on specific subgroups may shift, necessitating frequent modifications to ensure reports accurately reflect current study priorities.

Moreover, regulatory requirements and stakeholder expectations add further complexity, demanding strict compliance while adapting to changes in study design, endpoints, and patient demographics. Maintaining consistency across interim and final reports is crucial, requiring robust validation and quality control processes.

Handling large volumes of real-time data poses another challenge, especially in adaptive trials where treatments may change based on interim results. Statistical programmers must develop flexible, scalable reporting solutions that efficiently accommodate these adjustments while ensuring data integrity and minimizing inconsistencies.

CHALLENGES WITH REGULATORY SUBMISSIONS

Challenges with the submission packages in master protocols stem from the complexity of integrating data across multiple sub-studies while ensuring compliance with regulatory standards. Frequent protocol amendments require constant updates to datasets, metadata, and define.xml files, increasing the risk of inconsistencies. Handling large datasets with varying treatment arms and evolving study endpoints makes standardization difficult, requiring automated processes to maintain accuracy. Additionally, aligning SDTM, ADaM, and TLF outputs while ensuring traceability for regulatory review adds another layer of complexity. Version control, documentation, and efficient communication among cross-functional teams are crucial to overcoming these challenges and ensuring a seamless submission process.

CHALLENGES WITH MANAGING WORKLOAD

Programmers working on multiple protocols often face high-pressure environments, tight deadlines, and frequent changes, leading to stress and potential burnout. Managing diverse datasets and shifting priorities adds complexity, making it difficult to maintain efficiency and motivation. Constant protocol amendments, evolving regulatory requirements, and the need to maintain consistency across studies add to the workload. Managing multiple databases, adapting to dynamic analysis requests, and ensuring compliance with stringent submission guidelines create additional pressure. While exposure to various trial designs can be intellectually stimulating, the constant demand for adaptability can impact morale.

RECOMMENDATIONS FOR AN INDIVIDUAL CONTRIBUTOR

As a hands-on programmer, proactively planning and designing flexible, dynamic programs is essential to ensuring adaptability to evolving inputs and requests. A thorough understanding of the current trial

design, along with the ability to anticipate potential modifications—such as the addition or removal of treatment arms—allows for the development of a robust framework that minimizes disruptions. Beyond technical implementation, maintaining adaptability, leveraging automation and available resources, and continuously refining processes based on lessons learned are critical to managing uncertainties. Effective collaboration with cross-functional teams, clear documentation, and proactive troubleshooting further enhance the ability to respond to shifting requirements, ultimately supporting the efficient execution of clinical trials.

RECOMMENDATIONS FOR A LEADER

The success of an entire project ultimately rests on the leader's ability to guide and support the team effectively.

Focus on Process Improvement: A leader must prioritize process enhancement through knowledge sharing, brainstorming sessions, and targeted training programs to ensure that the team remains well-equipped and informed. Continuous improvement fosters efficiency and adaptability, both of which are essential in complex project environments. Introducing data dashboards or data visualization tools (such as an interactive RShiny dashboard) can significantly streamline data review and decision-making in clinical trials. These tools enable users to easily generate aggregates and visualize trends across various combinations of treatment arms and subgroups. By automating and simplifying the exploratory analysis process, the dashboard alleviates the burden on programming teams, allowing them to focus on higher-level analysis.

Resource Retention: Given that master protocols require long-term resource commitments, retaining skilled personnel is critical. Leaders can achieve this by providing essential tools, maintaining motivation, and helping the team stay focused under pressure. Recognizing individual contributions, fostering a collaborative work environment, and ensuring open communication with cross-functional teams further enhance engagement and job satisfaction. Additionally, leaders must effectively translate technical challenges and resource constraints into clear, actionable insights while negotiating realistic timelines.

Encourage Documentation: Comprehensive documentation of processes and study progress is essential to maintaining project continuity. Proper documentation ensures that ongoing work remains accessible and understandable for team members who may assume responsibilities mid-project. Furthermore, strategic resource planning helps prevent gaps, ensuring a seamless workflow and sustained project momentum.

CONCLUSION

Master protocols represent a significant evolution in clinical trial design, offering flexibility, efficiency, and the ability to test multiple hypotheses simultaneously. However, they also introduce unique challenges at every stage—from data retrieval and analysis to reporting and project management. The key to success in these trials lies in planning, adaptability, and strong communication. Individual contributors must be proactive in designing flexible solutions, while leaders must focus on fostering collaboration, maintaining resource continuity, and ensuring the smooth adaptation of the trial as it evolves. By addressing these challenges and embracing the inherent flexibility of master protocols, clinical trials can be conducted more efficiently, ultimately advancing medical research in a timely and cost-effective manner.

REFERENCES

1. Research, Center for Drug Evaluation and. "Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry." *U.S. Food and Drug Administration*, 2 Mar. 2022, www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and.

2 Woodcock, Janet, and Lisa M. LaVange. “Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.” *New England Journal of Medicine*, vol. 377, no. 1, 6 July 2017, pp. 62–70, https://doi.org/10.1056/nejmra1510062.

3. Bahl, Aman, and Syneos Health®. *Shifting the Drug Development Paradigm with Adaptive Design and Master Protocol*.

ACKNOWLEDGMENTS

I would like to express my heartfelt gratitude to my previous manager, Janette Garner, for her invaluable inspiration. My sincere thanks go to my current manager, Madhuri Doss, and Stephen Chan for their constant encouragement throughout the process of writing this paper. I am also deeply appreciative of my colleagues, Aniket Patil, for his thorough review, and Chaitanya Chowdagam for his help in creating the figures. A special thank you to my son, Leelakrishna Angadala, for his support in helping me format the paper.

CONTACT INFORMATION <HEADING 1>

Your comments and questions are valued and encouraged. Contact the author at:

Vijaya.L.Jonnalagadda
Associate Director, Statistical Programming.
Revolution Medicines
Email: ang.viju@gmail.com
https://www.linkedin.com/in/vijaya-jonnalagadda/